Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322. The company is slated to publish top-line data from an ongoing Phase I/II study of FX-322 in the first half of the year. Get the full story at our sister site, Drug […]
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in the […]
Lessons learned: How Jeff Karp stays at the forefront of innovation
Serial entrepreneur Jeff Karp has a philosophy for his laboratory: find important problems and get solutions to people quickly. To learn about the exciting technologies emerging from Karp’s lab, join us at DeviceTalks Boston on Oct. 8-10. After Jeff finished his PhD in chemical and biomedical engineering at the University of Toronto, he knew he wanted […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up visit […]
Biolase CEO Flynn steps down | Personnel Moves – April 13, 2018
Biolase (NSDQ:BIOL) said this week its CEO Harold Flynn has resigned from the company to pursue other interests, and that current CFO John Beaver will step in to act as interim CEO. The transition will be made immediately, the Irvine, Calif.-based company said. “I would like to thank Harold for the leadership and commitment he has […]
Invuity prez & CEO Sawyer steps down, Flora in as interim | Personnel Moves – March 13, 2018
Invuity (NSDQ:IVTY) said late last week that its president and chief executive officer Philip Sawyer has resigned and will be replaced by board member Scott Flora on an interim basis. Flora has served as a member of the board since last November, and has held positions as prez, CEO and director of Omniguide. He has also held […]
Frequency touts first-in-human safety study for hearing loss therapy
Frequency Therapeutics has finished a first-in-human study of its progenitor cell activation therapy, FX-322, in nine adults with severe to profound sensorineural hearing loss. The company’s candidate is a combination of small molecules that are designed to activate progenitor cells and trigger the formation of new hair cells in the inner ear. Get the full story […]
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly served as CEO of Alcresta, where he led regulatory and financing strategies for the company’s 1st product approval and launch. He also worked as Incline Therapeutics’ […]
Frequency raises $32m in Series A for hearing loss therapy
Frequency Therapeutics said today that it closed a $32 million Series A round, led by CoBro Ventures. Morningside Ventures, Emigrant Capital Corp., Korean Investment Partnership, Alexandria Real Estate Equities and other groups also invested in the round. The company has developed a proprietary combination of small molecule drugs that they plan to inject in the ear, […]
The stem cell therapy that could reverse hearing loss
Frequency Therapeutics is betting that it can change the lives of millions of Americans with hearing loss, by triggering the body’s natural ability to heal itself. Researchers have used cells in regenerative medicine for decades – in 1931, the father of cell therapy, Paul Niehans, treated a patient with material from calf embryos. Although today’s […]
Frequency Therapeutics names board of directors
Frequency Therapeutics named its board of directors last week, the company’s 1st public move since it was founded in 2015. Marc Cohen of COBRO Ventures was named chairman. Founder and former CEO of Sepracor, Inc., joined the board as well as Marc Kozin, senior advisor and former president of L.E.K. Consulting. Robert Langer, who co-founded […]
MassDevice Network
@MassDevice
LinkedIn
YouTube